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ABSTRACT 
Objective: Chronic Kidney Disease (CKD) is characterized by progressive loss of kidney function over a period of time. Sevelamer hydrochloride is a 
phosphate binding agent used to control serum phosphate levels in End Stage Renal Disease (ESRD) patients with hyperphosphatemia. Since 
hyperphosphatemia is associated with acute myocyte injury and elevation of cardiac biomarkers. ESRD patients treated with sevelamer 
hydrochloride display reduced cardiac biomarker levels due to a decrease in serum phosphate. Therefore, the study was designed to evaluate the 
effect of sevelamer hydrochloride on cardiac enzyme levels.  
Methods: This retrospective observational study was carried out in the nephrology department of a multispecialty hospital for a period of two 
months. Clinical and biochemistry reports of 30 ESRD patients were collected in designed case report forms. All statistical analysis was carried out 
using International Business Machines-Statistical Package for the Social Sciences, version 17 (IBM SPSS 17) Statistics package.  
Results: No significant difference in cardiac enzymes between sevelamer-treated and untreated groups was observed. Hence, further prospective 
studies on sevelamer hydrochloride are necessary to determine their activity in preventing hyperphosphatemia-induced acute myocyte injury. 
Conclusion: A direct correlation was observed between cardiac enzyme markers and phosphate levels. However, sevelamer at conventional doses 
was not found to be effective in reducing acute cardiomyocytes injury caused by hyperphosphatemia. Hence, higher doses sevelamer or other 
modalities achieving normal serum phosphorous levels are necessary for preventing cardiac damage due to hyperphosphatemia in ESRD patients. 
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INTRODUCTION 
CKD is a condition characterized by progressive deterioration of 
renal function and is defined as abnormalities of kidney structure or 
function, present for more than 3 mo, with implications for health 
[1]. Diabetes mellitus is one of the major causes of renal failure. 
Approximately 30% of patients with diabetic nephropathy 
eventually progress to end-stage renal failure and the rest usually 
die from cardiovascular disease before reaching end-stage [2]. 
Besides the major manifestations of CKD such as renal azotemia, 
phosphate retention remains a significant cause for secondary 
complications. Hyperphosphatemia due to phosphorus retention 
plays a major role in the development of secondary hyper-
parathyroidism and osteodystrophy in CKD patients [3]. It has also 
been shown that hyperphosphatemia leads to acute cardiomyocytes 
injury which could be a significant factor cause for cardiac 
complications in CKD patients [4]. Troponin T, Creatinine 
Phosphokinase (CPK) and Creatinine Kinase–MB (CK-MB) are 
specific biomarkers for determining cardiomyocytes damage. It has 
been shown that increased serum phosphorous levels display 
increased cardiac enzyme profiles thus suggesting a direct link 
between hyperphosphatemia and cardiac damage [5]. Sevelamer is a 
drug used to treat hyperphosphatemia in ESRD patients. It is used to 
prevent ectopic calcification resulting from precipitation of serum 
calcium due to hyperphosphatemia [6]. In addition, 
hyperphosphatemia provokes secondary hyperparathyroidism 
which in turn causes osteitis fibrosa [7]. Used either as the 
carbonate or hydrochloride salt, sevelamer binds to dietary 
phosphate and prevents its absorption into systemic circulation [8]. 
However, the effect of sevelamer on cardiomyocytes injury has not 
been evaluated in previous studies. Since hyperphosphatemia 
induces cardiac damage in ESRD patients, patients on sevelamer 
should possess cardioprotective properties by decreasing the 
systemic load of phosphorous to which the cardiomyocytes are 
exposed. Hence, this study was designed to evaluate the effect of 
sevelamer hydrochloride on cardiac damage.  
MATERIALS AND METHODS 
This was conducted as a retrospective observational study in the 
nephrology department of a multispecialty hospital for a period of six 
months. The study protocol was approved by the institutional ethics 
committee of Vels University (Approval no: IEC/DOP/2015/05). 
Consent from the hospital authorities and nephrologists were 
obtained before accessing the clinical records of patients. Clinical data 
was recorded from the patient case sheets stored in the medical 
records department of the hospital whereas biochemical parameters 
were recorded from the laboratory database. All the clinical and 
biochemistry data were recorded in a separate case report form. 
Levels of cardiac enzymes such as CK-MB, CPK and Troponin T where 
used as markers for assessing the cardiac damage.  
Inclusion criterion 
The study was conducted on 30 ESRD patients of both genders with 
hyperphosphatemia who were treated with sevelamer 
hydrochloride. A cardiac marker level of sevelamer-treated group 
was compared to a control with hyperphosphatemia that lacked 
sevelamer treatment.  
Exclusion criterion 
Patients with any of the four stages of CKD other than, ESRD patients 
without hyperphosphatemia, clinical records with insufficient data 
were excluded from the study. 
Statistical analysis 
All statistical analyses were performed using IBM SPSS 17 statistics 
package. Pearson’s correlation was used to determine the correlation 
and linear dependency of cardiac enzymes on serum phosphate levels. 
A paired t-test was used to compare serum phosphorous levels before 
and after treatment with sevelamer whereas an unpaired t-test was 
used to compare the cardiac enzyme profiles of sevelamer-treated and 
untreated groups. A p-value of less than 0.05 was considered 
statistically significant throughout the study.  
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The study included ESRD patients with hyperphosphatemia with or 
without sevelamer therapy. A Glomerular filtration rate (GFR) of less 
than 15 ml/min per 1.73 m2
Age group 
has been defined as ESRD by the 
National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative Classification and hence such patients were only included 
in the study [9]. Age wise distribution of patients included for the 
study is shown in table 1. 
 
Table 1: Age-wise distribution of patients included in the study 
Number of patients Percentage 
21-30 1 3.3 
31-40 0 0.0 
41-50 1 3.3 
51-60 6 20.0 
61-70 11 36.7 
71-80 7 23.3 
81-90 4 13.3 
Mean age=66.3 y, SD=13.3 y. 
 
Patients of both the gender were included in the study. Out of the 30 
patients, 60% were male whereas 40% were female. It is graphically 
represented in fig. 1.  
 
Fig. 1: Gender wise distribution of patients 
 
Serum Phosphate levels were correlated with estimated glomerular 
filtration rate to determine the linear dependency using Pearson’s 
correlation. The results are shown in table 2. 
In order to understand the dependency of cardiac enzyme levels 
with serum phosphorous levels, CK-MB, CPK and troponin T levels 
were individually correlated phosphorus levels using Pearson’s 
correlation. The results are shown in table 3. 
Since sevelamer is known to decrease serum phosphate levels in 
ESRD patients with hyperphosphatemia, we compared the serum 
phosphate levels of the studied subjects before and three months after 
treatment with sevelamer. A paired t-test was used to determine the 
statistically significant difference and is as shown in fig. 2. 
 
Table 2: Correlation of estimated glomerular filtration rate with serum phosphorous 
  Serum phosphorous GFR 
Serum phosphorous Pearson correlation 1 -.789** 
Significance (2-tailed)    .000 
N 30 30 
GFR Pearson correlation -.789** 1 
Significance (2-tailed) .000  
N 30 30 
**Correlation is significant at the 0.01 level (2-tailed), Serum Phosphate =-0.319 GFR+9.3779 
 
Table 3: Correlation coefficients of serum phosphorous with CK-MB, CPK-total and troponin t 
Parameters CK-MB CPK-total Troponin T 
Serum phosphorus 0.850** 0.835** 0.581** 
**Correlation is significant at the 0.01 level (2-tailed) 
 
Table 4: Comparison of cardiac enzyme levels in sevelamer treated and untreated groups 
Parameters (mg/dL) Sevelamer treated  (n= 14) Sevelamer untreated (n=16)   









Troponin T 0.8611 
* P values were retrieved by means of comparison of cardiac enzyme levels of sevelamer-treated and untreated patients using unpaired t-test 
 
 
Fig. 2: Comparison of serum phosphate levels before and after 
treatment with sevelamer–(P value<0.0001-paired t-test by 
comparison of serum phosphate levels of sevelamer pre-
treatment group against post-treatment group) 
In order to determine the effect of sevelamer on cardiac enzyme 
levels, unpaired t-tests were done to compare the CK-MB, CPK-total 
and troponin T levels in sevelamer-treated and untreated groups. 
The results are shown in table 4. 
DISCUSSION 
Elderly patients are more prone to the renal impairment associated 
hyperphosphatemia. Age is an important factor for renal impairment 
and chronic kidney disease [10]. In the studied population with ESRD 
associated hyperphosphatemia, the frequency of patients is high in the 
elderly group than the nonelderly. Hence elderly patients with ESRD are 
more susceptible to hyperphosphatemia associated complications. In the 
studied population of patients, 40% were male, and 60% were female.  
Serum creatinine is an endogenous marker for assessment of renal 
function. The modified diet in renal disease formula provides a modality 
for estimation of glomerular filtration rate from serum creatinine [11]. 
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The National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative classifies patients with a GFR of less than 15 ml/min per 1.73 
m2
Declared none. 
to have end-stage renal failure [9]. Therefore higher serum phosphate 
levels are observed in patients with lesser GFR. Pearson’s correlation 
was done to determine the effect of GFR on serum phosphate levels. A 
strong linear dependency was observed with a correlation coefficient of-
0.789. The negative slope indicates an inverse correlation: lower the 
GFR, higher the phosphate levels. This could be attributed to the fact that 
phosphate is retained with impaired renal function [12]. 
Hyperphosphatemia confers cardiac damage by inducing acute 
cardiomyocytes injury as a consequence of which the cardiac biomarker 
levels are elevated [5]. Hence, to determine the dependency of cardiac 
biomarker levels on serum phosphate levels, individual Pearson’s 
correlations were carried out. A Strong dependency exists between CK-
MB and serum phosphate, CPK and Serum phosphate with correlation 
coefficients of 0.850 and 0.835 respectively.  
Comparison of serum phosphate levels before and after treatment 
with sevelamer showed statistically significant difference at a 
confidence interval of 95%. Post-treatment serum phosphate levels 
were comparatively lower than the pre-treatment values suggesting 
that sevelamer treatment was effective in reducing phosphate levels 
in ESRD patients with hyperphosphatemia [13]. However, 
comparison of cardiac biomarker profiles between sevelamer-
treated and untreated groups did not show any statistically 
significant difference. Further prospective interventional studies are 
required to monitor and analyze the effect of phosphate on cardiac 
damage in ESRD patients with hyperphosphatemia.  
CONCLUSION 
A direct correlation was observed between cardiac enzyme markers 
and phosphate levels. However, sevelamer at conventional doses was 
not found to be effective in reducing acute cardiomyocytes injury 
caused by hyperphosphatemia. Hence, higher doses sevelamer or 
other modalities achieving normal serum phosphorous levels are 
necessary for preventing cardiac damage due to hyperphosphatemia 
in ESRD patients. Further prospective interventional studies are 
required to monitor and analyze the effect of phosphate on cardiac 
damage in CKD patients with decreased renal clearance there by 
preventing the development of cardiovascular complications.  
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